The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
NCT02416635 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2015-12-30
Summary
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in liver cancer could play an important role in diagnosis, predicting the risk for tumor recurrence, and providing novel target therapy biomarkers. In view of these facts, the investigators wanted to demonstrate the value of multiparameter flow cytometry in detecting human tumor cells of liver cancer in normal peripheral blood after cryosurgery with or without dendritic cell(DC)-cytokine-induced killers(CIK) treatment, and the investigators also compared the specificity with reverse transcriptase polymerase chain reaction (RT-PCR) method.
Conditions
- Neoplastic Cells, Circulating
Interventions
- OTHER
-
Flow cytometry (FCM)
Use FCM to test PBMCs/CTCs from volunteers/patients.
- OTHER
-
RT-PCR
Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Sponsors & Collaborators
-
Fuda Cancer Hospital, Guangzhou
lead OTHER
Eligibility
- Min Age
- 15 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2015-12-31
- Completion
- 2015-12-31
Countries
- China
Study Locations
More Related Trials
-
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers
NCT05622825 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
NCT04152356 ·Status: UNKNOWN
-
Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment
NCT04143516 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer
NCT02843802 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
NCT04163237 ·Status: UNKNOWN ·Phase: PHASE3
-
Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence
NCT02032368 ·Status: COMPLETED ·Phase: NA
-
Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
NCT06408753 ·Status: COMPLETED
-
Effect of Nutritional Indices on the Prognosis of HCC Patients
NCT05635279 ·Status: COMPLETED
-
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
NCT06265350 ·Status: RECRUITING ·Phase: NA
-
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
NCT06405321 ·Status: RECRUITING
-
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer
NCT05371873 ·Status: UNKNOWN
-
Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic Treatments
NCT05443217 ·Status: UNKNOWN
-
Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome
NCT02329106 ·Status: COMPLETED ·Phase: NA
-
a Cohort Study (Gut Microbiota and HCC)
NCT06557213 ·Status: NOT_YET_RECRUITING
-
Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection
NCT02738697 ·Status: UNKNOWN ·Phase: PHASE3
-
Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
NCT06540508 ·Status: ENROLLING_BY_INVITATION
-
Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer
NCT05160740 ·Status: RECRUITING ·Phase: NA
-
Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer
NCT00769106 ·Status: COMPLETED ·Phase: PHASE3
-
Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)
NCT05835245 ·Status: RECRUITING ·Phase: PHASE2
-
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
NCT06157060 ·Status: RECRUITING
-
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
NCT02352935 ·Status: COMPLETED ·Phase: NA
-
A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
NCT06205732 ·Status: RECRUITING
-
Observational Study on Patients With Hepatobiliary Tumors
NCT04637048 ·Status: UNKNOWN
-
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
NCT05292443 ·Status: WITHDRAWN
-
CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis
NCT04512833 ·Status: RECRUITING